Avidity Biosciences' CEO Sarah Boyce discusses the company's Exon 44 skipping data in DMD that showed a 25% increase in dystrophin production

blonca9
Aug 13, 2024
1 min read

She describes how this PMO based antibody oligonucleotide conjugate works and why she believes the result validates her belief that Avidity has the strongest delivery in the field.

Recent Posts

See All

With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers

Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals

Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using its CryptoMap platform

Avidity Biosciences' CEO Sarah Boyce discusses the company's Exon 44 skipping data in DMD that showed a 25% increase in dystrophin production

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight